BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci 2020;21:E6968. [PMID: 32971948 DOI: 10.3390/ijms21186968] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang P, Li Q, Zhang Y, Wang Q, Yan J, Shen A, Hu B. Identification of a Novel Gene Signature with DDR and EMT Difunctionalities for Predicting Prognosis, Immune Activity, and Drug Response in Breast Cancer. Int J Environ Res Public Health 2023;20. [PMID: 36673982 DOI: 10.3390/ijerph20021221] [Reference Citation Analysis]
2 Castoldi A, Lee J, de Siqueira Carvalho D, Souto FO. CD8+ T cell metabolic changes in breast cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2023;1869:166565. [DOI: 10.1016/j.bbadis.2022.166565] [Reference Citation Analysis]
3 Baldwin XL, Spanheimer PM, Downs-canner S. A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research 2023;281:289-298. [DOI: 10.1016/j.jss.2022.08.040] [Reference Citation Analysis]
4 Elsaka RO, Helal SM, Abdelhady AM, Kolaib NM, Soliman MA. Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis. Alexandria Journal of Medicine 2022;58:92-101. [DOI: 10.1080/20905068.2022.2101083] [Reference Citation Analysis]
5 Dai Y, Zhao L, Hua D, Cui L, Zhang X, Kang N, Qu L, Li L, Li H, Shen D, Wang Z, Wang J. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. Front Immunol 2022;13:1035616. [PMID: 36532042 DOI: 10.3389/fimmu.2022.1035616] [Reference Citation Analysis]
6 Spathas N, Goussia AC, Koliou GA, Gogas H, Zagouri F, Batistatou A, Charchanti AV, Papoudou-Bai A, Bobos M, Chrisafi S, Chatzopoulos K, Kostopoulos I, Koletsa T, Arapantoni P, Pectasides D, Galani E, Koutras A, Zarkavelis G, Saloustros E, Bafaloukos D, Karanikiotis C, Bompolaki I, Aravantinos G, Psyrri A, Razis E, Koumarianou A, Res E, Linardou H, Fountzilas G. Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. Cancers (Basel) 2022;14. [PMID: 36428728 DOI: 10.3390/cancers14225635] [Reference Citation Analysis]
7 Zhang P, Li Q, Zhang Y, Wang Q, Yan J, Shen A, Hu B. Identification of a novel gene signature with DDR and EMT difunctionalities for predicting prognosis, immune activity, and drug response in breast cancer.. [DOI: 10.21203/rs.3.rs-2220137/v1] [Reference Citation Analysis]
8 Ferguson AL, Sharman AR, Allen RO, Ye T, Lee JH, Low TH, Ch'ng S, Palme CE, Ashford B, Ranson M, Clark JR, Patrick E, Gupta R, Palendira U. High-Dimensional and Spatial Analysis Reveals Immune Landscape-Dependent Progression in Cutaneous Squamous Cell Carcinoma. Clin Cancer Res 2022;28:4677-88. [PMID: 36044477 DOI: 10.1158/1078-0432.CCR-22-1332] [Reference Citation Analysis]
9 Zhu Y, Zhang H, Pan C, He G, Cui X, Yu X, Zhang X, Wu D, Yang J, Wu X, Luo H, Liu X. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer. Cancer Med 2022. [PMID: 36271505 DOI: 10.1002/cam4.5372] [Reference Citation Analysis]
10 Zhong Y, Ren X, Cao X, Xu Y, Song Y, Zhou Y, Mao F, Shen S, Wang Z, Sun Q. Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis. Front Oncol 2022;12:871786. [DOI: 10.3389/fonc.2022.871786] [Reference Citation Analysis]
11 Peterko AC, Rajković-Molek K, Gulić T, Vujaklija DV, Lovasić IB, Lovasić F, Mustać E, Avirović M. HSP70 In triple negative breast cancer: Prognostic value and clinical significance. Pathol Res Pract 2022;238:154127. [PMID: 36174439 DOI: 10.1016/j.prp.2022.154127] [Reference Citation Analysis]
12 Wang H, Liu H, Wang L, Xu S, Pi H, Cheng Z, Zheng M. Subtype Classification and Prognosis Signature Construction of Osteosarcoma Based on Cellular Senescence-Related Genes. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/4421952] [Reference Citation Analysis]
13 Oshi M, Patel A, Wu R, Le L, Tokumaru Y, Yamada A, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. NPJ Breast Cancer 2022;8:92. [PMID: 35945417 DOI: 10.1038/s41523-022-00466-2] [Reference Citation Analysis]
14 Ye Z. Identification of T cell-related biomarkers for breast cancer based on weighted gene co-expression network analysis. J Chemother 2022;:1-9. [PMID: 35822502 DOI: 10.1080/1120009X.2022.2097431] [Reference Citation Analysis]
15 Zhou Y, Tian Q, Gao H, Zhu L, Zhang Y, Zhang C, Yang J, Wang B. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling. Front Immunol 2022;13:859581. [DOI: 10.3389/fimmu.2022.859581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li C, Wang X, Chen T, Li W, Zhou X, Wang L, Yang Q. Huaier Induces Immunogenic Cell Death Via CircCLASP1/PKR/eIF2α Signaling Pathway in Triple Negative Breast Cancer. Front Cell Dev Biol 2022;10:913824. [DOI: 10.3389/fcell.2022.913824] [Reference Citation Analysis]
17 Ferguson A, Sharman A, Allen R, Ye T, Lee J, Low H, Ch’ng S, Palme C, Ashford B, Ranson M, Clark J, Patrick E, Gupta R, Palendira U. High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma.. [DOI: 10.1101/2022.04.19.488697] [Reference Citation Analysis]
18 Tank A, Vergato C, Waxman DJ, Roblyer D. Spatial frequency domain imaging for monitoring immune-mediated chemotherapy treatment response and resistance in a murine breast cancer model. Sci Rep 2022;12:5864. [PMID: 35393476 DOI: 10.1038/s41598-022-09671-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K. High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06552-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers 2022;14:1323. [DOI: 10.3390/cancers14051323] [Reference Citation Analysis]
21 Lee C, Lee H, Cho H, Kim S, Choi I, Hwang YS, Jeong H, Jang H, Pak S, Hwang DS, Han IH, Bae H. Combination of anti-PD-L1 antibody with peptide MEL-dKLA targeting M2 tumor-associated macrophages suppresses breast cancer metastasis. Cancer Commun (Lond) 2022. [PMID: 35171513 DOI: 10.1002/cac2.12276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li S, Fang Y. MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis. Med Sci Monit 2022;28:e934597. [PMID: 35091527 DOI: 10.12659/MSM.934597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zheng X, Zhou X, Xu H, Jin D, Yang L, Shen B, Qiu S, Ai J, Wei Q. A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer. Front Genet 2021;12:764184. [PMID: 34899849 DOI: 10.3389/fgene.2021.764184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Chen N, Higashiyama N, Hoyos V. Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1. Biomedicines 2021;9:1863. [PMID: 34944679 DOI: 10.3390/biomedicines9121863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Osuna-Gómez R, Arqueros C, Galano C, Mulet M, Zamora C, Barnadas A, Vidal S. Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy. Cancers (Basel) 2021;13:6167. [PMID: 34944786 DOI: 10.3390/cancers13246167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Ta HDK, Minh Xuan DT, Tang WC, Anuraga G, Ni YC, Pan SR, Wu YF, Fitriani F, Putri Hermanto EM, Athoillah M, Andriani V, Ajiningrum PS, Wang CY, Lee KH. Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer. Biomedicines 2021;9:1804. [PMID: 34944621 DOI: 10.3390/biomedicines9121804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Al-Rashidi HE, Refaat S, Ahmed E, Hussein DT, Eltantawy FM, Hamed S. Involvement of INF-γ functional single nucleotide polymorphism +874 T/A (rs2430561) in breast cancer risk. Saudi J Biol Sci 2021;28:6289-96. [PMID: 34759748 DOI: 10.1016/j.sjbs.2021.06.083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pomatto-Watson LCD, Bodogai M, Bosompra O, Kato J, Wong S, Carpenter M, Duregon E, Chowdhury D, Krishna P, Ng S, Ragonnaud E, Salgado R, Gonzalez Ericsson P, Diaz-Ruiz A, Bernier M, Price NL, Biragyn A, Longo VD, de Cabo R. Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nat Commun 2021;12:6201. [PMID: 34707136 DOI: 10.1038/s41467-021-26431-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
29 He Y, Wu Y, Liu Z, Li B, Jiang N, Xu P, Xu A. Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer. Front Genet 2021;12:694777. [PMID: 34589112 DOI: 10.3389/fgene.2021.694777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Noh MG, Kim SS, Kim YJ, Jung TY, Jung S, Rhee JH, Lee JH, Lee JS, Cho JH, Moon KS, Park H, Lee KH. Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy. Cancers (Basel) 2021;13:4895. [PMID: 34638378 DOI: 10.3390/cancers13194895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Yang WB, Qin CP, Du YQ, Han SC, Xu T. Siglec-15 promotes progression of clear renal cell carcinoma. Chin Med J (Engl) 2021;134:2635-7. [PMID: 34561324 DOI: 10.1097/CM9.0000000000001752] [Reference Citation Analysis]
32 Ali DA, El-Guindy DM, Elrashidy MA, Sabry NM, Kabel AM, Gaber RA, Ibrahim RR, Samy SM, Shalaby MM, Salama SA, Abdelhai D. The Prognostic Significance of MACC1 Expression in Breast Cancer and Its Relationship to Immune Cells in the Tumor Microenvironment and Patient Survival. Medicina (Kaunas) 2021;57:934. [PMID: 34577857 DOI: 10.3390/medicina57090934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Patel A, Oshi M, Yan L, Matsuyama R, Endo I, Takabe K. The Unfolded Protein Response Is Associated with Cancer Proliferation and Worse Survival in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4443. [PMID: 34503253 DOI: 10.3390/cancers13174443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Pang H, Zhang W, Liang X, Zhang Z, Chen X, Zhao L, Liu K, Galiullin D, Yang K, Chen X, Hu J. Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study. Adv Ther 2021;38:4917-34. [PMID: 34379305 DOI: 10.1007/s12325-021-01870-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
35 Lai J, Lin X, Cao F, Mok H, Chen B, Liao N. CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients. J Cell Mol Med 2021;25:9390-401. [PMID: 34464504 DOI: 10.1111/jcmm.16880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ma Q, Chen Y, Qin Q, Guo F, Wang Y, Li D. CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration. Precision Clinical Medicine 2021;4:155-67. [DOI: 10.1093/pcmedi/pbab020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Singh DD, Yadav DK. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines 2021;9:876. [PMID: 34440080 DOI: 10.3390/biomedicines9080876] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Tokumaru Y, Oshi M, Huyser MR, Yan L, Fukada M, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. Sci Rep 2021;11:14134. [PMID: 34239017 DOI: 10.1038/s41598-021-93681-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Costa REARD, Oliveira FTRD, Araújo ALN, Vieira SC. Prognostic factors in triple-negative breast cancer: a retrospective cohort. Rev Assoc Med Bras 2021;67:950-957. [DOI: 10.1590/1806-9282.20210249] [Reference Citation Analysis]
40 Oshi M, Tokumaru Y, Angarita FA, Lee L, Yan L, Matsuyama R, Endo I, Takabe K. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep 2021;11:12541. [PMID: 34131208 DOI: 10.1038/s41598-021-91897-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
41 Okano M, Oshi M, Mukhopadhyay S, Qi Q, Yan L, Endo I, Ohtake T, Takabe K. Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival. Cancers (Basel) 2021;13:2933. [PMID: 34208219 DOI: 10.3390/cancers13122933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Fan T, Lu Z, Liu Y, Wang L, Tian H, Zheng Y, Zheng B, Xue L, Tan F, Xue Q, Gao S, Li C, He J. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis. Front Immunol 2021;12:665407. [PMID: 34177903 DOI: 10.3389/fimmu.2021.665407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
43 Mathias C, Muzzi JCD, Antunes BB, Gradia DF, Castro MAA, Carvalho de Oliveira J. Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes. Front Oncol 2021;11:692170. [PMID: 34136413 DOI: 10.3389/fonc.2021.692170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
44 Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. Cancers (Basel) 2021;13:2559. [PMID: 34071012 DOI: 10.3390/cancers13112559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:2401. [PMID: 34065619 DOI: 10.3390/cancers13102401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Liu M, Zheng Q, Chen S, Liu J, Li S. FUT7 Promotes the Epithelial-Mesenchymal Transition and Immune Infiltration in Bladder Urothelial Carcinoma. J Inflamm Res 2021;14:1069-84. [PMID: 33790621 DOI: 10.2147/JIR.S296597] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
47 Oshi M, Huyser MR, Le L, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer. Cancers (Basel) 2021;13:1477. [PMID: 33807015 DOI: 10.3390/cancers13061477] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
48 Oshi M, Tokumaru Y, Mukhopadhyay S, Yan L, Matsuyama R, Endo I, Takabe K. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Cells 2021;10:653. [PMID: 33804148 DOI: 10.3390/cells10030653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
49 Tokumaru Y, Oshi M, Patel A, Tian W, Yan L, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Organoids Are Limited in Modeling the Colon Adenoma-Carcinoma Sequence. Cells 2021;10:488. [PMID: 33668713 DOI: 10.3390/cells10030488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Oshi M, Kim TH, Tokumaru Y, Yan L, Matsuyama R, Endo I, Cherkassky L, Takabe K. Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2021;13:323. [PMID: 33477315 DOI: 10.3390/cancers13020323] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
51 Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer. Cancers (Basel) 2020;12:E3856. [PMID: 33371179 DOI: 10.3390/cancers12123856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
52 Oshi M, Tokumaru Y, Patel A, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Cancers (Basel) 2020;12:E3635. [PMID: 33291601 DOI: 10.3390/cancers12123635] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
53 Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I, Takabe K. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers (Basel) 2020;12:E3557. [PMID: 33260779 DOI: 10.3390/cancers12123557] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
54 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Kalinski P, Endo I, Takabe K. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). Cancers (Basel) 2020;12:E3342. [PMID: 33198125 DOI: 10.3390/cancers12113342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
55 Schulze A, Oshi M, Endo I, Takabe K. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer. Int J Mol Sci 2020;21:E8127. [PMID: 33143224 DOI: 10.3390/ijms21218127] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]